Trontinemab: A New Brain-Penetrant Alzheimer’s Therapy | Dr. Gil Rabinovici

A new generation of Alzheimer’s therapies is tackling one of medicine’s toughest challenges: delivering drugs to the brain. Renowned Alzheimer’s researcher Dr. Gil Rabinovici explores trontinemab, an investigational anti-amyloid therapy being studied for early Alzheimer’s disease that uses innovative Brainshuttle™ technology to enhance drug delivery across the blood-brain barrier. He also shares insights from the TRONTIER 1 and 2 clinical trials, the TRAVELLER pre-screening study, and the ambitious PrevenTRON prevention study, which is exploring whether early treatment may help stop or prevent symptoms altogether in people at high risk for Alzheimer’s disease. For a deeper dive into trontinemab, watch our full conversation with Dr. Rabinovici, part of the Zoom In on Dementia and Alzheimer’s series: https://www.brightfocus.org/resource/trontinemab-a-new-brain-penetrant-alzheimers-therapy/ Support for Let’s Talk Alzheimer’s is provided by sponsors Lilly, Biogen, Eisai, and Genentech. Let’s Talk Alzheimer’s is presented by Alzheimer’s Disease Research, a BrightFocus Foundation program. We fund exceptional research across the globe to support the development of cutting-edge treatments, risk reduction strategies, and ultimately a cure for this mind-stealing disease. Visit brightfocus.org to learn more and get involved.